Replies to post #33201 on Biotech Values

[DewDiligence]

NBIX – If your assertion about the timing of the FDA meetings is correct (as I’m sure it is), I would say the company’s scheduling of the option re-pricing on Sep 26 makes the odds against good news from the FDA meetings overwhelming. This is as strong a harbinger of the outcome of an FDA meeting as I’ve seen in a long while.

By the way, I assume that top management will take care of itself too in due course. As you know, timing option grants to follow bad news is not a securities violation (although perhaps it ought to be). Regards, Dew